银屑病关节炎患者血清tP1NP、β-CTX、OC、25-(OH)VD_3水平变化及意义
|
摘要
目的探讨银屑病关节炎(Ps A)患者血清总Ⅰ型前胶原氨基端延长肽(t P1NP)、Ⅰ型胶原羧基端肽β特殊序列(β-CTX)、N-端骨钙素(OC)、25-羟维生素D3[25-(OH)VD_3)]水平变化及其临床意义。方法选择51例Ps A患者作为观察组,其中骨质破坏19例、无骨质破坏32例,28例健康体检者作为对照组。采用电化学发光法检测两组血清骨标记物t P1NP、β-CTX、OC及25-(OH)VD_3,并分析血清骨标记物水平与Ps A患者病情相关指标(年龄、病程、血沉及血清CRP)的关系。结果观察组血清t P1NP、β-CTX、OC水平均高于对照组(P<0.05或<0.01),两组血清25-(OH)VD_3水平比较差异无统计学意义(P>0.05)。观察组有骨质破坏者血清t P1NP、OC水平均高于无骨质破坏者(P均<0.01),有、无骨质破坏者血清β-CTX、25-(OH)VD_3水平比较差异均无统计学意义(P均>0.05)。血清t P1NP、β-CTX、OC、25-(OH)VD_3水平与Ps A患者年龄、病程、血沉及血清CRP水平均无关(P均>0.05)。观察组有骨质破坏者血清t P1NP水平与血沉呈正相关(r=0.557,P<0.05),血清β-CTX、OC、25-(OH)VD_3水平与患者病情相关指标均无关(P均>0.05)。结论 Ps A患者血清t P1NP、β-CTX、OC水平均升高;血清t P1NP水平有助于判断Ps A患者骨质破坏及病情活动程度。
引文
[1]Myers WA,Gottlieb AB,Mease P.Psoriasis and psoriatic arthritis:clinical features and disease mechanisms[J].Clin Dematol,2006,24(5):438-447.
[2]Ronti T,Lupattelli G,Mannarino E.The endocrine function of adipose tissue:an update[J].Clin Endocrinol(Oxf),2006,64(4):355-365.
[3]Gladman DD,Farewell VT,Nadeau C.Clinical indicators of progression in psoriatic arthritis:multivariate relative risk model[J].J Rheumatol,1995,22(4):675-679.
[4]Moll JM,Wright V.Psoriatic arthritis[J].Semin Arthritis Rheum,1973(3):55-78.
[5]Schwarz EM,Looney RJ,Drissi MH,et al.Autoimmunity and bone[J].Ann N Y Acad Sci,2006,1068(1):275-283.
[6]Lockhart E,Green AM,Flynn JL.IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection[J].J Immunol,2006,177(7):4662-4669.
[7]Mantravadi S,Ogdie A,Kraft WK.Tumor necrosis factor inhibitors in psoriatic arthritis[J].Expert Rev Clin Pharmacol,2016(22):1-12.
[8]Gladman DD,Antoni C,Mease P,et al.Psoriatic arthritis:epidemiology,clinical features,course and outcome[J].Ann Rheum Dis,2005,64(suppl2):l4-l7.
[9]Recker RR,Marin F,Ish-Shalom S,et al.Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis[J].J Bone Miner Res,2009,24(8):1358-1368.
[10]刘石平,廖二元,伍贤平,等.尿Ⅰ型胶原羧基末端肽和氨基末端肽排泄率与年龄、绝经和绝经后骨丢失的关系[J].中华医学杂志,2006,86(6):371-375.
[11]Mc Gonagle D.Enthesitis:an autoinflammatory lesion linking nail and joint involvement in psoriatic disease[J].J Eur Acad Dermatol Venereol,2009,23(Suppl 1):9-13.
[12]Franck H,Ittel T.Serum osteocalcin levels in patients with psoriatic arthritis:an extended report[J].Rheumatol Int,2000,19(5):161-164.
[13]Braun J,Bollow M,Sieper J.Radiologic diagnosis and pathology of the spondyloarthropathies[J].Rheum Dis Clin North Am,1998,24(4):697-735.
[14]Soleymani T,Hung T,Soung J.The role of vitamin D in psoriasis:a review[J].Int J Dermatol,2015(54):383-392.
[15]Kincse G,Bhattoa PH,Heredi E,et al.Vitamin D3 levels and bone mineral density in patients with psoriasis and/or psoriatic arthritis[J].J Dermatol,2015,42(7):679-684.
[16]Kirylow E,Kaminski G.Place of biochemical markers of bone turnover in guidelines for diagnosis and treatment of osteoporosis[J].Pol Merkur Lekarski,2008,25(148):386-389.
[17]Nolla JM,Fiter J,Rozadilla A,et al.Bone mineral density in patients with peripheral psoriatic arthritis[J].Rev Rhum Engl Ed,1999,66(10):457-461.
[18]Gladman DD,Mease PJ,Strand V,et al.Consensus on a core set of domains for psoriatic arthritis[J].J Rheumatol,2007(34):1167-1170.
[19]Mease PJ.Assessment tools in psoriatic arthritis[J].J Rheumatol,2008(35):1426-1430.
[20]Mease PJ,CE Antoni,Gladman DD,et al.Psoriatic arthritis assessment tools in clinical trials[J].Ann Rheum Dis,2005,64(Suppl 2):49-54.
[21]Maejima H,Taniguchi T,Watarai A,et al.Analysis of clinical,radiological and laboratory variables in psoriatic arthritis with 25Japanese patients[J].J Dermatol,2010,37(7):647-656.
[22]Gladman DD,Mease PJ,Choy EH,et al.Risk factors for radiographic progression in psoriatic arthritis:subanalysis of the randomized controlled trial ADEPT[J].Arthritis Res Ther,2010,12(3):113.
[2]Ronti T,Lupattelli G,Mannarino E.The endocrine function of adipose tissue:an update[J].Clin Endocrinol(Oxf),2006,64(4):355-365.
[3]Gladman DD,Farewell VT,Nadeau C.Clinical indicators of progression in psoriatic arthritis:multivariate relative risk model[J].J Rheumatol,1995,22(4):675-679.
[4]Moll JM,Wright V.Psoriatic arthritis[J].Semin Arthritis Rheum,1973(3):55-78.
[5]Schwarz EM,Looney RJ,Drissi MH,et al.Autoimmunity and bone[J].Ann N Y Acad Sci,2006,1068(1):275-283.
[6]Lockhart E,Green AM,Flynn JL.IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection[J].J Immunol,2006,177(7):4662-4669.
[7]Mantravadi S,Ogdie A,Kraft WK.Tumor necrosis factor inhibitors in psoriatic arthritis[J].Expert Rev Clin Pharmacol,2016(22):1-12.
[8]Gladman DD,Antoni C,Mease P,et al.Psoriatic arthritis:epidemiology,clinical features,course and outcome[J].Ann Rheum Dis,2005,64(suppl2):l4-l7.
[9]Recker RR,Marin F,Ish-Shalom S,et al.Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis[J].J Bone Miner Res,2009,24(8):1358-1368.
[10]刘石平,廖二元,伍贤平,等.尿Ⅰ型胶原羧基末端肽和氨基末端肽排泄率与年龄、绝经和绝经后骨丢失的关系[J].中华医学杂志,2006,86(6):371-375.
[11]Mc Gonagle D.Enthesitis:an autoinflammatory lesion linking nail and joint involvement in psoriatic disease[J].J Eur Acad Dermatol Venereol,2009,23(Suppl 1):9-13.
[12]Franck H,Ittel T.Serum osteocalcin levels in patients with psoriatic arthritis:an extended report[J].Rheumatol Int,2000,19(5):161-164.
[13]Braun J,Bollow M,Sieper J.Radiologic diagnosis and pathology of the spondyloarthropathies[J].Rheum Dis Clin North Am,1998,24(4):697-735.
[14]Soleymani T,Hung T,Soung J.The role of vitamin D in psoriasis:a review[J].Int J Dermatol,2015(54):383-392.
[15]Kincse G,Bhattoa PH,Heredi E,et al.Vitamin D3 levels and bone mineral density in patients with psoriasis and/or psoriatic arthritis[J].J Dermatol,2015,42(7):679-684.
[16]Kirylow E,Kaminski G.Place of biochemical markers of bone turnover in guidelines for diagnosis and treatment of osteoporosis[J].Pol Merkur Lekarski,2008,25(148):386-389.
[17]Nolla JM,Fiter J,Rozadilla A,et al.Bone mineral density in patients with peripheral psoriatic arthritis[J].Rev Rhum Engl Ed,1999,66(10):457-461.
[18]Gladman DD,Mease PJ,Strand V,et al.Consensus on a core set of domains for psoriatic arthritis[J].J Rheumatol,2007(34):1167-1170.
[19]Mease PJ.Assessment tools in psoriatic arthritis[J].J Rheumatol,2008(35):1426-1430.
[20]Mease PJ,CE Antoni,Gladman DD,et al.Psoriatic arthritis assessment tools in clinical trials[J].Ann Rheum Dis,2005,64(Suppl 2):49-54.
[21]Maejima H,Taniguchi T,Watarai A,et al.Analysis of clinical,radiological and laboratory variables in psoriatic arthritis with 25Japanese patients[J].J Dermatol,2010,37(7):647-656.
[22]Gladman DD,Mease PJ,Choy EH,et al.Risk factors for radiographic progression in psoriatic arthritis:subanalysis of the randomized controlled trial ADEPT[J].Arthritis Res Ther,2010,12(3):113.